Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin coronary syndrome trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck/Schering-Plough are initiating a 10,000-patient trial to evaluate the efficacy of their Zetia/Zocor combo Vytorin (ezetimibe/simvastatin) in reducing morbidity and mortality in high-risk acute coronary syndrome patients, the firms announce Nov. 9. IMPROVE IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) will compare Vytorin 10 mg/40 mg to Zocor 40 mg for the composite primary endpoint of death, myocardial infarction, rehospitalization for ACS or revascularization. The study follows Merck's "A to Z" trial of Zocor in ACS, which signaled an increased risk of myopathy with Zocor 80 mg...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002718

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel